Compare WVE & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | FDMT |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 673.9M | 695.3M |
| IPO Year | 2015 | 2019 |
| Metric | WVE | FDMT |
|---|---|---|
| Price | $3.69 | $12.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 12 |
| Target Price | $17.11 | ★ $28.09 |
| AVG Volume (30 Days) | ★ 3.0M | 970.1K |
| Earning Date | 10-27-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | $3,704,000.00 | ★ $85,209,000.00 |
| Revenue This Year | $46.45 | N/A |
| Revenue Next Year | N/A | $55.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 149.43 | ★ 230194.60 |
| 52 Week Low | $3.04 | $6.96 |
| 52 Week High | $21.73 | $16.93 |
| Indicator | WVE | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 49.43 |
| Support Level | $3.04 | $8.43 |
| Resistance Level | $4.07 | $13.73 |
| Average True Range (ATR) | 0.20 | 0.90 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 76.83 | 73.28 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).